论文部分内容阅读
目的 :研究探讨血清β2 微球蛋白 (β2 - MG)在鉴别良恶性消化系疾病中的价值。方法 :用放射免疫法测定 12 0例消化系癌肿和 10 8例消化系良性疾病患者的血清β2 - MG水平 ,用 3 6例正常人作对照。结果 :消化系恶性肿瘤比消化系良性疾病和正常人的血清β2 - MG明显增高 (P<0 .0 1)。良性疾病中仅溃疡性结肠炎血清β2 - MG较其它良性疾病和正常人明显升高 (P<0 .0 1) ,与结肠癌比较无差异 (P<0 .0 5 )。高β2 - MG血症发生率消化系恶性肿瘤 (60 .83 % )较良性疾病(14 .81% )明显增高 (P<0 .0 1)。血清β2 - MG增高在进展期癌肿中占 92 .5 2 % ,相对稳定期癌肿中仅占 5 1.61% (P<0 .0 1)。结论 :血清β2 - MG有助于鉴别消化系良恶性疾病。动态观察癌肿的血清β2 - MG变化对判断癌肿进展、预后、复发有一定价值。
Objective: To investigate the value of serum β2 microglobulin (β2 - MG) in differentiating benign and malignant digestive diseases. Methods: Serum β2 - MG level was measured by radioimmunoassay in 120 cases of digestive cancer and 108 cases of benign diseases of digestive system, and 36 healthy controls were used as controls. Results: The malignant tumors of the digestive system were significantly higher than the benign diseases of the digestive system and the normal serum β2 - MG (P <0.01). In benign diseases, ulcerative colitis serum β2 - MG was significantly higher than other benign diseases and normal people (P <0.01), but no difference with colon cancer (P <0.05). The incidence of high β2 - MG hyperlipidemia (60.83%) was significantly higher than that of benign disease (14.81%) (P <0.01). Serum β2 - MG increased 92.52% in advanced cancer and only 5.61% in stable cancer (P <0.01). Conclusion: Serum β2 - MG is helpful to distinguish benign and malignant digestive diseases. Dynamic observation of cancer serum β2 - MG changes in the judgment of cancer progression, prognosis, relapse have some value.